A 5-year venom immunotherapy protocol with 50μg maintenance dose: Safety and efficacy in school children

Pediatric Allergy and Immunology

Volumn 22, Issue 4, 2011, Pages 393-397

  Konstantinou, George N ^a   Manoussakis, Emmanuel ^a   Douladiris, Nikolaos ^a   Hatziioannou, Anastasios ^a   Giavi, Stavroula ^a   Saxoni Papageorgiou, Photini ^a   Papadopoulos, Nikolaos G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Children; Common wasp; Honey bee; Maintenance dose; Venom hypersensitivity; Venom immunotherapy

Indexed keywords

HYMENOPTERA VENOM; VENOM;

ABSENCE OF SIDE EFFECTS; ANAPHYLAXIS; ARTICLE; CHILD; CLINICAL PROTOCOL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYMENOPTERA; HYPERSENSITIVITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INSECT STING; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANAPHYLAXIS; ANIMALS; CHILD; CLINICAL PROTOCOLS; DESENSITIZATION, IMMUNOLOGIC; FOLLOW-UP STUDIES; HUMANS; HYMENOPTERA; HYPERSENSITIVITY; INSECT BITES AND STINGS; POPULATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOMS;

EID: 79955523170     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2010.01137.x     Document Type: Article

References (27)

1. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Muller U. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005: 60: 1459-70.
2. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Eng J Med 2004: 351: 668-74.
3. Moffitt JE, Golden DB, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol 2004: 114: 869-86.
4. Hoffman DR, Jacobson RS. Allergens in hymenoptera venom XII: how much protein is in a sting? Ann Allergy 1984: 52: 276-8.
5. Schumacher MJ, Tveten MS, Egen NB. Rate and quantity of delivery of venom from honeybee stings. J Allergy Clin Immunol 1994: 93: 831-5.
6. Lerch E, Muller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998: 101: 606-12.
7. Reisman RE, Livingston A. Venom immunotherapy: 10years of experience with administration of single venoms and 50μg maintenance doses. J Allergy Clin Immunol 1992: 89: 1189-95.
8. Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res 1966: 3: 331-3.
9. Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN. Diagnosis of Hymenoptera venom allergy. Allergy 2005: 60: 1339-49.
10. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001: 108: 1027-32.
11. Reisman RE. Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. J Allergy Clin Immunol 1992: 90: 335-9.
12. van derLinden PW, Hack CE, Struyvenberg A, van derZwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol 1994: 94: 151-9.
13. Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992: 89: 529-35.
14. Golden DB, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981: 67: 370-4.
15. Golden DB, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980: 92: 620-4.
16. Bilo MB, Antonicelli L, Bonifazi F. Purified vs. nonpurified venom immunotherapy. Curr Opin Allergy Clin Immunol 2010: 10: 330-6.
17. Houliston L, Nolan R, Noble V, et al. Honeybee venom immunotherapy in children using a 50-mug maintenance dose. J Allergy Clin Immunol 2010: doi:
18. Mueller U, Reisman R, Wypych J, et al. Comparison of vespid venoms collected by electrostimulation and by venom sac extraction. J Allergy Clin Immunol 1981: 68: 254-61.
19. Sanchez F, Blanca M, Fernandez J, et al. Comparative study between European and American species of Polistes using sera from European sensitized subjects. Clin Exp Allergy 1995: 25: 281-7.
20. Severino MG, Campi P, Macchia D, et al. European Polistes venom allergy. Allergy 2006: 61: 860-3.
21. Hoffman DR. Structural biology of allergens from stinging and biting insects. Curr Opin Allergy Clin Immunol 2008: 8: 338-42.
22. Bilo MB, Severino M, Cilia M, et al. The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts. Ann Allergy Asthma Immunol 2009: 103: 57-61.
23. Cadario G, Marengo F, Ranghino E, et al. Higher frequency of early local side effects with aqueous versus depot immunotherapy for hymenoptera venom allergy. J Investig Allergol Clin Immunol 2004: 14: 127-33.
24. Alessandrini AE, Berra D, Rizzini FL, et al. Flexible approaches in the design of subcutaneous immunotherapy protocols for Hymenoptera venom allergy. Ann Allergy Asthma Immunol 2006: 97: 92-7.
25. Rodger MA, King L. Drawing up and administering intramuscular injections: a review of the literature. J Adv Nurs 2000: 31: 574-82.
26. Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000: 105: 385-90.
27. Oude ElberinkJN, De MonchyJG, Van Der Heide S, Guyatt GH, Dubois AE. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002: 110: 174-82.